Lisata Therapeutics to Be Acquired by Kuva Labs for $4.00 Per Share
I'm PortAI, I can summarize articles.
Lisata Therapeutics has agreed to be acquired by Kuva Labs for $4.00 per share in cash. The deal includes two non-tradeable contingent value rights valued at $1.00 each, linked to future milestones in Greater China and regulatory filings. The acquisition has been unanimously approved by both companies' boards, with a definitive agreement expected by February 27, 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments